Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)

Next Previous
Trial Profile

A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dmxirbesartan/propagermanium (Primary) ; Azilsartan medoxomil; Candesartan cilexetil; Irbesartan; Losartan; Olmesartan medoxomil; Telmisartan; Valsartan
  • Indications Focal segmental glomerulosclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ACTION3
  • Sponsors Dimerix Bioscience

Most Recent Events

  • 04 Sep 2026 According to a Dimerix media release, company plans to use the initial funding to support its planned clinical development activities, including the delivery and completion of ACTION3 phase 3 trial of DMX-200.
  • 12 Aug 2026 Planned number of patients changed from 311 to 356.
  • 06 Aug 2026 According to BioMarin Pharmaceutical Inc. media release, data from this trial data expected in 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top